# US 2024/0197745 A1 · Compositions and methods for treating, preventing or reversing age associated inflammation and disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197745 A1
- Document ID: US20240197745A1
- Status: Published application
- Kind: A1
- Application number: 18/470,182
- Filed: 2023-09-19
- Published: 2024-06-20
- Earliest claimed: 2019-01-25
- Assignees: Brown University
- Applicants: Brown University
- Inventors: John M. SEDIVY; Marco DE CECCO
- Web page: https://patentgrep.com/patent/US20240197745A1

## CPC

- A61K 31/52: Purines, e.g. adenine
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is a method for preventing, delaying or reversing age-associated inflammation, by administering to a patient in need thereof a therapeutically effective amount of at least one reverse transcriptase inhibitor (RTI).

## Claims

### Claim 1

A method for treating Alzheimer's disease, amyotrophic lateral sclerosis, autism spectrum disorder, dementia with Lewy Bodies, frontotemporal dementia, mild cognitive impairment, Parkinson's disease, progressive supra nuclear palsy, Rett Syndrome, or Aicardi-Goutieres syndrome in a patient in need thereof, the method comprising administering a therapeutically effective amount of censavudine.

### Claim at position 2

2-23. (canceled)

### Claim 24 (depends on 1)

The method of claim 1 comprising administering about 1 μg/kg to about 100 mg/kg of censavudine to the patient per day.

### Claim 25 (depends on 24)

The method of claim 24 comprising administering about 1 mg/kg to about 50 mg/kg of censavudine to the patient per day.

### Claim 26 (depends on 25)

The method of claim 25 comprising administering about 5 mg/kg of censavudine to the patient per day.

### Claim 27 (depends on 25)

The method of claim 25 comprising administering about 10 mg/kg of censavudine to the patient per day.

### Claim 28 (depends on 25)

The method of claim 25 comprising administering about 15 mg/kg of censavudine to the patient per day.

### Claim 29 (depends on 25)

The method of claim 25 comprising administering about 20 mg/kg of censavudine to the patient per day.

### Claim 30 (depends on 1)

The method of claim 1 comprising administering 1 mg to 500 mg of censavudine to the patient once a day, twice a day, or three times a day.

### Claim 31 (depends on 30)

The method of claim 30 comprising administering 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, or 150 mg of censavudine to the patient once a day, twice a day, or three times a day.

### Claim 32 (depends on 1)

The method of claim 1, wherein the censavudine is orally administered to the patient in the form of a tablet, capsule, or suspension.

### Claim 33 (depends on 1)

The method of claim 1 for treating Alzheimer's disease.

### Claim 34 (depends on 1)

The method of claim 1 for treating amyotrophic lateral sclerosis.

### Claim 35 (depends on 1)

The method of claim 1 for treating autism spectrum disorder.

### Claim 36 (depends on 1)

The method of claim 1 for treating dementia with Lewy Bodies.

### Claim 37 (depends on 1)

The method of claim 1 for treating frontotemporal dementia.

### Claim 38 (depends on 1)

The method of claim 1 for treating mild cognitive impairment.

### Claim 39 (depends on 1)

The method of claim 1 for treating Parkinson's disease.

### Claim 40 (depends on 1)

The method of claim 1 for treating progressive supra nuclear palsy.

### Claim 41 (depends on 1)

The method of claim 1 for treating Rett Syndrome.

### Claim 42 (depends on 1)

The method of claim 1 for treating Aicardi-Goutieres syndrome.
